---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-049549"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:45:32.661472+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics presents data showing POZ-lipid avoids anti-PEG immune response in animal model

## Summary
- POZ-lipid did not induce IgM or IgG antibody responses after repeated administration in an animal model.
- Standard PEG-lipids used in mRNA vaccines (Pfizer-BioNTech, Moderna) elicited robust IgM and IgG responses.
- Anti-PEG responses are linked to hypersensitivity reactions including anaphylaxis; POZ-lipid may enable safer LNP formulations.
- Randall Moreadith, MD, PhD, Chief Development Officer, presented at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston.

## SEC filing metadata
- accession: 0001493152-24-049549
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000149315224049549/0001493152-24-049549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000149315224049549/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-049549
- JSON: https://secwatch.observer/filing/0001493152-24-049549.json
- Plain text: https://secwatch.observer/filing/0001493152-24-049549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.